WELLESLEY HILLS, Mass. — September 4, 2025 — Leads & Copy — Climb Bio, Inc. (Nasdaq: CLYM) will host a webcast event on Monday, September 29, 2025, at 8:00 a.m. ET, to discuss its CLYM116 program, featuring leading nephrologist Dr. Craig E. Gordon.
The event will highlight CLYM116, a preclinical-stage monoclonal antibody targeting APRIL for treating IgA nephropathy (IgAN). The company plans to file an IND or CTA for CLYM116 in the second half of 2025.
The webcast will cover an overview of IgAN, preclinical data comparing CLYM116 to a first-generation anti-APRIL monoclonal antibody, and the company’s development strategy. Live access and a replay will be available on the Climb Bio website.
Carlo Tanzi, Ph.D., of Kendall Investor Relations, can be reached at ctanzi@kendallir.com.
Source: Climb Bio, Inc.
